Front Oncol:卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌(HCC)的有效性和安全性

2021-10-24 yd2015 MedSci原创

研究表明,卡瑞利珠单抗联合索拉非尼治疗晚期肝细胞癌疗效良好并且毒性可控。然而,需要更多的前瞻性随机试验进一步验证这种联合治疗的临床益处。

肝细胞癌(HCC)是一种高度侵袭性的恶性肿瘤,预后差。免疫治疗因其良好的临床疗效而引起人们对各种实体肿瘤的极大兴趣。靶向治疗在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大学附属第二医院团队开展了回顾性研究,旨在探讨卡瑞利珠单抗联合索拉非尼治疗晚期HCC的有效性和安全性。相关结果发表在Frontiers in Oncology杂志上。

研究于2019年1月至2021年1月连续纳入该院100例晚期HCC患者。患者被分为两组:联合治疗组(卡瑞利珠单抗+索拉非尼)和索拉非尼单药组。评估无进展生存期(PFS)、总生存期(OS)、治疗反应和相关不良反应(AEs)。

2019年1月至2021年1月期间,共纳入100例晚期HCC患者,其中联合治疗35例,索拉非尼单药治疗65例,中位随访8.8个月(范围3.9-13.0)。经倾向性评分(PSM)后各有34例患者。PSM前后的两组临床特征基本平衡。

             PSM前后的疗效评估

两组均未观察到完全缓解(CR)。PSM前,联合治疗组的ORR显著高于索拉非尼单药组(17.1% vs. 3.1%,p = 0.037)。联合治疗组DCR为68.6%,索拉非尼单药组DCR为72.3%,两组差异无统计学意义(p = 0.695)。两组间的OS无显著差异,联合治疗组的中位OS为14.1个月(6.8 -21.4个月),索拉非尼单药组的中位OS为9.6个月(6.7-12.5个月)(p = 0.135)。然而,与索拉非尼单药组相比,联合治疗组的无进展生存期(PFS)明显延长(10.2个月(95% CI: 4.5-19.0个月)vs. 6.1个月(95% CI: 2.5-9.7个月),p = 0.041)。

                   PSM前PFS和OS

PSM后观察到类似的结果。联合治疗组的ORR为17.6%,索拉非尼单药组为0.0% (p = 0.010)。两组的DCR相同(70.6%)(p = 1.000)。联合治疗组的中位OS为14.1个月(95% CI: 7.2-21.0个月),索拉非尼单药组的中位OS为9.6个月(95% CI: 6.1-13.1个月) (p = 0.105)。联合治疗组的中位无进展生存期(PFS)显著长于索拉非尼单药组(为9.5个月(95% CI: 1.2-17.8个月) vs 4.7个月(95% CI: 1.6-7.8个月) ,p = 0.043)。

              PSM后PFS和OS

在联合治疗组中最常见的AE为手足综合征、血小板减少症和高胆红素血症,在索拉非尼单药组中为手足综合征。然而,这些AEs大多为1级或2级,在调整剂量和支持治疗后很容易缓解。因AEs引起的剂量改变或治疗中断在联合治疗组和索拉非尼组中相似(PSM前:42.9% vs. 41.5%, p = 0.899; PSM后:42.9% vs. 41.2%,p = 0.806)。两组索拉非尼的剂量减少也类似 (PSM前:28.6% vs. 16.9%,p = 0.173; PSM后:29.4% vs. 14.7%,p = 0.144)。本研究中未发生治疗相关死亡。尽管PSM后联合治疗组比索拉非尼组有更高的发生率,如血小板减少,但大多数AEs在治疗后很容易控制。

          PSM前后不良事件

综上,研究表明,卡瑞利珠单抗联合索拉非尼治疗晚期肝细胞癌疗效良好并且毒性可控。然而,需要更多的前瞻性随机试验进一步验证这种联合治疗的临床益处。

原始出处:

Liu Q, You N, Li J, Wu K, Peng X, Wang Z, Wang L, Zhu Y and Zheng L (2021) Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Front. Oncol. 11:694409.doi: 10.3389/fonc.2021.694409

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-12-11 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2022-09-25 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-11-21 hykd12345

    ORR 17.6%还是不够看啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-26 仁医06
  7. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-25 JZ Yang

    PSM前后

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 11 00:56:15 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979219, encodeId=bc8819e921900, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Feb 04 16:56:15 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863614, encodeId=43b81863614b8, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 25 17:56:15 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687771, encodeId=3329168e77168, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat Dec 18 08:56:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072588, encodeId=c12210e2588c7, content=ORR 17.6%还是不够看啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/bT9AbnG9cnM46HCIxNtxgoxE1mq17o5qgAXuS51h5fzbBKy8zaF1hQibaE0ZLhMKrk6qfFsagLicRzlTTNBzBxAQ/0, createdBy=f4991982527, createdName=hykd12345, createdTime=Sun Nov 21 18:53:23 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368213, encodeId=e67813682139c, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502870, encodeId=01f515028e0c5, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36526, encryptionId=d56636526e4, topicName=卡瑞利珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d779566916, createdName=by2012, createdTime=Tue Oct 26 05:56:15 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063647, encodeId=2bcd106364ed3, content=PSM前后, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Oct 25 07:06:54 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063488, encodeId=b5a31063488c9, content=在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 17:29:23 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-24 ms9000000212834100

    在抗癌治疗中也发挥着重要作用。然而,免疫治疗与靶向治疗相结合治疗晚期HCC的研究还很有限。因此,军医大

    0

相关资讯

Lancet oncol:Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼!

信迪利单抗联合IBI305作为一线治疗方案用于不可手术切除的HBV相关肝癌患者,可提供优于索拉非尼治疗的总生存期和无进展生存期

Liver Cancer:阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期!

与索拉非尼单药治疗相比,阿特珠单抗联合贝伐单抗也可显著延长中国晚期 HCC 患者的无进展生存期和总生存期

Liver Cnacer:mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性:II期临床研究

mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌安全性可耐受,但没有达到研究终点。NGS分析mTOR通路突变跟肿瘤治疗反应无明显相关。

Clin Cancer Res:预测仑伐替尼(Lenvatinib)在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

基线高表达的VEGF, FGF21,和ANG2可能是较差OS的预后标志物;而基线高表达的FGF21是仑伐替尼较索拉非尼改善预后的预测标志物,这些还需要进一步的证实。

Br J Cancer:晚期肝细胞癌患者诊断性活检的可行性分析

早在2001年欧洲肝脏研究协会(EASL)首次定义了用于诊断肝细胞癌(HCC)的无创放射学标准(NIRC),并随着时间的推移不断的完善该标准。

Front Oncol:FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后

肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,是癌症相关死亡的第二大原因。晚期HCC患者常用索拉非尼治疗,但个体异质性差异较大,中位总生存时间(OS)仅为6.5-10.7个月。肝动脉灌注化疗(HAI